Nivolumab with ipilimumab for untreated advanced renal cell carcinoma

2.1 Nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) has a marketing authorisation for 'the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma'.

2.2 The dosage schedule is available in summary of product characteristic for nivolumab.

2.3 The list price of nivolumab is £2,633 per 240 mg per 24‑ml vial (excluding VAT; BNF online, accessed January 2022). The list price of ipilimumab is £15,000 per 200 mg per 40‑ml vial (excluding VAT; BNF online, accessed January 2022). The company has commercial arrangements for nivolumab with ipilimumab (simple discount patient access schemes). These make nivolumab and ipilimumab available to the NHS with discounts. The sizes of the discounts are commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discounts.